Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024 LONDON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Genflow Biosciences Plc (Genflow or the "Company”) (LSE:GENF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics...

Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024 Genflow Biosciences Plc ("Genflow" or "the Company") LONDON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The Company (LSE:GENF) (OTCQB:GENFF), an emerging leader in the field of longevity research...

Genflow Biosciences Partners with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants LONDON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Genflow Biosciences Plc (Genflow or the "Company”) (LSE:GNF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics...

Genflow Biosciences PLC Announces Company Update Successful first regulatory interaction with the Federal Agency for Medicines and Health Products (FAHMP) And Internal Debt Restructuring First regulatory agency interaction results in...